Core Viewpoint - Gain Therapeutics, Inc. is advancing its lead drug candidate GT-02287 for the treatment of Parkinson's disease, with promising preclinical data suggesting disease-modifying potential [1][5]. Group 1: Presentation Details - Joanne Taylor, Ph.D., will present on GT-02287 at the AD/PD™ 2025 International Conference, scheduled for April 1-5, 2025, in Vienna, Austria [1][2]. - The presentation will focus on GT-02287's potential in preclinical models of both GBA1 and idiopathic Parkinson's disease [2]. Group 2: Drug Candidate Overview - GT-02287 is an orally administered, brain-penetrant small molecule that acts as an allosteric modulator of the glucocerebrosidase enzyme, which is often impaired due to GBA1 mutations [4][7]. - Preclinical studies have shown that GT-02287 restores GCase function, reduces neuroinflammation, and improves motor and cognitive functions [4][5]. Group 3: Funding and Support - Gain Therapeutics has received funding from The Michael J. Fox Foundation, The Silverstein Foundation, and the Eurostars-2 program, indicating strong support for its research initiatives [6]. Group 4: Company Background - Gain Therapeutics is a clinical-stage biotechnology company focused on developing next-generation allosteric therapies for neurodegenerative diseases and other challenging disorders [8]. - The company utilizes its Magellan™ platform to discover novel small molecule modulators aimed at restoring protein function [8].
Gain Therapeutics Announces Oral Presentation at AD/PD 2025